GSK, Sanofi Launch Final Trials for New Covid-19 Vaccine

Summary

  • GSK, Sanofi launched the final phase III trials of their delayed Covid vaccine.
  • The phase III trial for the vaccine have 35,000 people enrolled, who are 18 years and above from different countries.
  • The trial would study the efficiency of the vaccine against both the original strain as well as the B.1.351 variant, detected first in South Africa.

British pharmaceutical company GSK Plc (LON: GSK) and France’s Sanofi on Thursday said that they had launched the final trials of their delayed Covid vaccine.

The phase III trail for the vaccine have 35,000 people enrolled, who are 18 years and above from different countries like Latin America, Africa, Asia, and the USA. The trial would study the efficiency of the vaccine against both the original strain as well as the B.1.351 variant, detected first in South Africa.

What is planned

As of December, Britain has pre-ordered about 60 million doses of the vaccine. The GSK vaccine was supposed to have got the necessary regulatory approvals by the first half of the year but got delayed in December after failing to get a credible immune response in older people.

Also read: Growing role of AI in healthcare: Pharma giants make big investments in 2020

The announcement came after the approval of sotrovimab, an antibody treatment, by the US Food and Drug Administration (FDA) for the therapy of mild-to-moderate coronavirus patients in the  age group of 12 years or above.

GSK’s shares were down 1.05 per cent and were trading at GBX 1,339 on 27 May at 13:09 GMT+1. The FTSE 100 was down 0.19 per cent at 7,013.89.

Image Source-Refinitiv

The clinical studies that would begin in the coming weeks would focus on the efficiency of the vaccine as a second dose if the first was a different jab. It would also study the efficiency of the vaccine on the original coronavirus strain and then look at the efficacy of the variant that originated in South Africa.

Sanofi’s global head Thomas Triomphe said that it was encouraging to see the first vaccination beginning at such a pivotal Phase 3 study. He said that the company believed that its technology platform would help to provide a vaccine option that would be clinically relevant.

Vaccine efficacy

The companies would also focus on studying the efficacy of the vaccine as a booster dose in people already vaccinated with other vaccines.

After the initial setback, the company announced earlier this month that its protein-based vaccine was able to produce antibodies in 95 to 100 per cent of the cases after they could successfully adapt their formula.

Their phase 2 trials had been successful in showing a strong immune response post a single shot in those who had been previously infected by the virus.

Triomphe said that the company adopted a forward-looking vaccine development strategy as the virus situation was a fast evolving one and was also anticipating what could be required in a post-pandemic setting.

The EU has so far approved four vaccines, namely, AstraZeneca/Oxford University, Pfizer/BioNTech,  Moderna and Johnson & Johnson, the last being a single-dose.

Sanofi and GSK said that the vaccine was on track to being approved in the last quarter of this year. Most of the adult population of the UK, US and the EU are expected to have been fully vaccinated by then.  


Disclaimer
The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is not authorised or regulated by the Financial Conduct Authority to provide regulated advice. The purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. The Content is guidance about the different types of investments that are available and sets out general principles to continue before making investment decisions. Kalkine Media is neither authorised nor qualified to provide regulated investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from an appropriately authorised and/or qualified financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.